Literature DB >> 19324423

Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment.

Louise A Hurst1, Rowena A D Bunning, Pierre-Olivier Couraud, Ignacio A Romero, Babette B Weksler, Basil Sharrack, M Nicola Woodroofe.   

Abstract

ADAM-17 expression is localised to endothelial cells in the human central nervous system (CNS) and is increased in multiple sclerosis (MS) white matter, suggesting a role in MS pathogenesis. Expression of ADAM-17, TIMP-3, and fractalkine were investigated in a human brain endothelial cell line (hCMEC/D3) after pro-inflammatory cytokine treatment. Tumour necrosis factor (TNF) significantly increased fractalkine mRNA (>100 fold) and protein expression, which was associated with increased shedding of fractalkine from the cell. Fractalkine shedding may regulate immune cell trafficking into the CNS, however, this does not appear to be directly controlled by ADAM-17 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324423     DOI: 10.1016/j.jneuroim.2009.02.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.

Authors:  G Alkistis Frentzou; Claire Bradford; Kirsty A Harkness; Gail Haddock; M Nicola Woodroofe; Alison K Cross
Journal:  J Mol Neurosci       Date:  2011-07-06       Impact factor: 3.444

2.  Human brain endothelial cells are responsive to adenosine receptor activation.

Authors:  Jeffrey H Mills; Leah Alabanza; Babette B Weksler; Pierre-Olivier Couraud; Ignacio A Romero; Margaret S Bynoe
Journal:  Purinergic Signal       Date:  2011-02-17       Impact factor: 3.765

3.  DNA Subtraction of In Vivo Selected Phage Repertoires for Efficient Peptide Pathology Biomarker Identification in Neuroinflammation Multiple Sclerosis Model.

Authors:  Karina Vargas-Sanchez; Antonios Vekris; Klaus G Petry
Journal:  Biomark Insights       Date:  2016-02-16

Review 4.  The Therapeutic Potential of Monocyte/Macrophage Manipulation in the Treatment of Chemotherapy-Induced Painful Neuropathy.

Authors:  Karli Montague; Marzia Malcangio
Journal:  Front Mol Neurosci       Date:  2017-11-27       Impact factor: 5.639

Review 5.  The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain.

Authors:  Karli Montague; Marzia Malcangio
Journal:  J Neurochem       Date:  2017-02-24       Impact factor: 5.372

6.  The hCMEC/D3 cell line as a model of the human blood brain barrier.

Authors:  Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud
Journal:  Fluids Barriers CNS       Date:  2013-03-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.